Long-yun Ye
88 Jiefang Road
Hangzhou, 310009, China
Hangzhou, 310009, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 23 publications
The GFPT2-O-GlcNAcylation-YBX1 axis promotes IL-18 secretion to regulate the tumor immune microenvironment in pancreatic cancer.
Journal: Cell death & disease
Published: November 29, 2023
Deubiquitinating PABPC1 by USP10 upregulates CLK2 translation to promote tumor progression in pancreatic ductal adenocarcinoma.
Journal: Cancer letters
Published: July 19, 2023
Inhibition of epithelial-to-mesenchymal transition augments antitumor efficacy of nanotherapeutics in pancreatic ductal adenocarcinoma.
Journal: The FEBS journal
Published: February 08, 2023
Follicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets.
Follicle-stimulating hormone orchestrates glucose-stimulated insulin secretion of pancreatic islets.
Journal: Nature communications
Published: May 29, 2022
SIGLEC15 amplifies immunosuppressive properties of tumor-associated macrophages in pancreatic cancer.
Journal: Cancer letters
Published: November 08, 2021
Infiltrating pattern and prognostic value of tertiary lymphoid structures in resected non-functional pancreatic neuroendocrine tumors.
Journal: Journal for immunotherapy of cancer
Published: September 21, 2020
Neutrophil Extracellular Traps and Macrophage Extracellular Traps Predict Postoperative Recurrence in Resectable Nonfunctional Pancreatic Neuroendocrine Tumors.
Journal: Frontiers in immunology
Published: August 14, 2020
Advances on diagnostic biomarkers of pancreatic ductal adenocarcinoma: A systems biology perspective.
Journal: Computational and structural biotechnology journal
Published: July 31, 2020
A novel risk factor panel predicts early recurrence in resected pancreatic neuroendocrine tumors.
Journal: Journal of gastroenterology
Published: July 29, 2020
Tumor-Infiltrating Neutrophils Predict Poor Survival of Non-Functional Pancreatic Neuroendocrine Tumor.
Journal: The Journal of clinical endocrinology and metabolism
Published: February 01, 2020
Isocorydine decrease gemcitabine-resistance by inhibiting epithelial-mesenchymal transition via STAT3 in pancreatic cancer cells.
Journal: American journal of translational research
Published: January 21, 2020
Isocorydine suppresses doxorubicin-induced epithelial-mesenchymal transition via inhibition of ERK signaling pathways in hepatocellular carcinoma.
Journal: American journal of cancer research
Published: November 06, 2017
Last Updated: 09/26/2026